View Author
scopus: 7801327198

Mearadji, A.

(Amir Mearadji)


tumor patient liver metastase imatinib disease treatment effect therapy control cd 117 expression liver metastases group stromal tumors resection study stromal lu-dota expression somatostatin result metastatic surgery octreotide cancer receptor month control rats tumor cells antitumor effect experiment tumor score response cc 2b metastatic gist signi antitumor ssr-positive specimen table survival imatinib treatment model toxicity radionuclide tissue range score ssr-negative 177 lu imatinib therapy control group number colony cc 531 portal vein ssr expression autoradiography r 0 resection resected specimen resected animal ficant breeman wa radiologic bystander effect radioactivity carcinoma subtype metastatic disease stomach signi ficantly colon stromal tumours bystander effect progression uptake bystander follow-up 0.5 metastasi




2 Most Recent Publications

Decrease of CD117 expression as possible prognostic marker for recurrence in the resected specimen after imatinib treatment in patients with initially unresectable gastrointestinal stromal tumors: A clinicopathological analysis (Article)
Mearadji, A. Bakker, M.A. den Geel, A.N. van Eggermont, A.M.M. Sleijfer, S. Verweij, J. Wilt, J.H.W. de Verhoef, C.
2008-07-01
Somatostatin receptor gene therapy combined with targeted therapy with radiolabeled octreotide: a new treatment for liver metastases. (Article)
Mearadji, A. Breeman, W.A.P. Hofland, L.J. Marquet, R.L. Jeekel, J. Krenning, E.P. Eijck, C.H.J. van Koetsveld, P.M. van
2002-01-01